Malaria
Conditions
Interventions
Group 1:A naphthoquine-azithromycin compounded formulation(400mg)
Group 2:A naphthoquine-azithromycin compounded formulation(800mg)
Sponsors
Yunnan Institute of Parasitic Diseases
Eligibility
Sex/Gender
All
Age
5 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) All subjects voluntarily signed informed consents before the trial; (2) Ranged in age from 5–65 years-of-age male or female; (3) Subjects with no medical history or otherwise physically healthy; (4) Fertile woman pregnancy tests should be negative; (5) With 1 month prior to the screening were not participating in another trial.
Exclusion criteria
Exclusion criteria: (1) In the screening period had malaria symptoms or were positive for Plasmodium parasites according to a blood smear; (2) had a history of malaria in past two weeks; (3) had received antimalarial therapy in the past two weeks; (4) had received malaria prophylaxis in the past three months; (5) had a known or suspected allergy to macrolides, naphthoquine, or other product components; (6) had known or suspected liver and kidney dysfunction; (7) known or suspected poor compliance; (8) pregnant or lactating women; (9) had another disease(s) that might affect the assessment of therapeutic efficacy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Protection rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Median time and mean time for smear positive;Total Positive rate of blood smear;Total Positive rate of blood smear;Cumulative life-incidence and otal Positive rate of blood smea; | — |
Countries
China
Contacts
Public ContactHenglin Yang
Yunnan Institute of Parasitic Diseases
Outcome results
None listed